We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
-14.02%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$270M
AUM Growth
+$46.4M
(+21%)
Cap. Flow
+$86.8M
Cap. Flow
% of AUM
32.16%
Top 10 Holdings %
Top 10 Hldgs %
7.48%
Holding
501
New
128
Increased
202
Reduced
102
Closed
67
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Realty Income
O
|
+$931K |
| 2 |
SK Telecom
SKM
|
+$871K |
| 3 |
Moderna
MRNA
|
+$825K |
| 4 |
ConocoPhillips
COP
|
+$786K |
| 5 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$785K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Agnico Eagle Mines
AEM
|
+$1.83M |
| 2 |
BPMP
BP Midstream Partners LP Common Units representing Limited Partner Interests
BPMP
|
+$1.76M |
| 3 |
The Mosaic Company
MOS
|
+$928K |
| 4 |
STR
Sitio Royalties
STR
|
+$559K |
| 5 |
Gold Fields
GFI
|
+$512K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 18.55% |
| 2 | Healthcare | 17.07% |
| 3 | Materials | 11.98% |
| 4 | Financials | 11.43% |
| 5 | Energy | 8.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Theravance Biopharma
TBPH
$874M
| $246K | 0.09% |
27,109
-9,250
| -25% | -$85.2K |
|
|
CCXI
302
DELISTED
ChemoCentryx, Inc.
CCXI
| $246K | 0.09% |
9,930
-1,284
| -11% | -$28.3K |
|
303
OFS Capital
OFS
$46M
| $245K | 0.09% |
24,742
-7,755
| -24% | -$93.8K |
|
|
ITCI
304
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $245K | 0.09% |
4,296
-6,123
| -59% | -$347K |
|
305
Biogen
BIIB
$29.5B
| $244K | 0.09% |
1,195
-417
| -26% | -$85.2K |
|
306
Amgen
AMGN
$203B
| $240K | 0.09% |
985
-755
| -43% | -$185K |
|
307
Travere Therapeutics
TVTX
$5.27B
| $239K | 0.09% |
9,875
-4,241
| -30% | -$107K |
|
308
Mirum Pharmaceuticals
MIRM
$6.96B
| $236K | 0.09% |
12,137
+976
| +9% | +$23K |
|
|
SAGE
309
DELISTED
Sage Therapeutics
SAGE
| $235K | 0.09% |
7,281
-2,313
| -24% | -$77.5K |
|
310
Halozyme
HALO
$9.66B
| $234K | 0.09% |
5,324
-5,414
| -50% | -$234K |
|
311
Ironwood Pharmaceuticals
IRWD
$644M
| $234K | 0.09% |
20,267
-13,795
| -40% | -$163K |
|
312
Acadia Pharmaceuticals
ACAD
$4.35B
| $201K | 0.07% |
14,280
-1,892
| -12% | -$35.3K |
|
|
KZR
313
DELISTED
Kezar Life Sciences
KZR
| $182K | 0.07% |
2,197
+943
| +75% | +$83.2K |
|
|
MRSN
314
DELISTED
Mersana Therapeutics
MRSN
| $161K | 0.06% |
1,392
+260
| +23% | +$24.5K |
|
315
Atara Biotherapeutics
ATRA
$69.5M
| $157K | 0.06% |
804
+409
| +104% | +$66.8K |
|
316
PMV Pharmaceuticals
PMVP
$62.9M
| $157K | 0.06% |
10,986
+4,240
| +63% | +$61.7K |
|
|
AGEN
317
Agenus
AGEN
$255M
| $155K | 0.06% |
4,064
+1,524
| +60% | +$55.3K |
|
318
Lyell Immunopharma
LYEL
$318M
| $150K | 0.06% |
+1,147
| New | +$117K |
|
319
BioXcel Therapeutics
BTAI
$26.8M
| $149K | 0.06% |
705
+223
| +46% | +$46.9K |
|
320
Iovance Biotherapeutics
IOVA
$2.19B
| $148K | 0.05% |
13,415
+4,752
| +55% | +$62.3K |
|
|
SRNE
321
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $148K | 0.05% |
73,547
+48,120
| +189% | +$83.2K |
|
322
C4 Therapeutics
CCCC
$397M
| $145K | 0.05% |
19,169
+13,894
| +263% | +$122K |
|
323
Gossamer Bio
GOSS
$97.5M
| $145K | 0.05% |
17,370
+2,331
| +15% | +$18.1K |
|
324
uniQure
QURE
$2.63B
| $144K | 0.05% |
7,750
+2,237
| +41% | +$35.6K |
|
|
IMGN
325
DELISTED
Immunogen Inc
IMGN
| $144K | 0.05% |
32,106
+7,260
| +29% | +$31.5K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2022 Portfolio in Review
As of Q2 2022, Virtus ETF Advisers held 501 positions worth $270M, up 21% from $223M the previous quarter. Its ten largest holdings account for 7.5% of the portfolio.
Virtus ETF Advisers deployed $86.8M of net new capital in Q2 2022, opening 128 new positions and adding to 202 existing holdings. Its largest new stake was ConocoPhillips: 7,627 shares worth $685K.
By sector, the portfolio is most concentrated in Real Estate at 19% of assets, down from 20% a quarter earlier, followed by Healthcare and Materials.
On the sell side, the largest reduction was Agnico Eagle Mines, an estimated $1.83M trimmed.
- Virtus ETF Advisers's largest Q2 2022 buy was ConocoPhillips: 7,627 shares worth $685K.
- Virtus ETF Advisers added most to Realty Income in Q2 2022, an estimated $931K increase.
- Virtus ETF Advisers's biggest Q2 2022 reduction was Agnico Eagle Mines, cutting an estimated $1.83M.
- Virtus ETF Advisers fully exited BP Midstream Partners LP Common Units representing Limited Partner Interests in Q2 2022, selling an estimated $1.76M.
- Virtus ETF Advisers's ten largest holdings make up 7.5% of its $270M portfolio in Q2 2022.
- Virtus ETF Advisers opened 128 new positions and closed 67 in Q2 2022.
- Virtus ETF Advisers's portfolio value rose 21% quarter-over-quarter to $270M.
Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.